Results from Two Studies Show Soticlestat Efficacy for CDD and Dup15q Syndrome
https://pixabay.com/en/epilepsy-seizure-stroke-headache-623346/

Results from Two Studies Show Soticlestat Efficacy for CDD and Dup15q Syndrome

  Developmental and epileptic encephalopathies (DEEs), or rare epilepsies, are somewhat of a newer topic. However, researchers are already making strides in creating treatments to address unmet patient needs. On…

Continue Reading Results from Two Studies Show Soticlestat Efficacy for CDD and Dup15q Syndrome
Initial Trial Data Looks Promising for a Potential Treatment for Rare Epilepsies
geralt / Pixabay

Initial Trial Data Looks Promising for a Potential Treatment for Rare Epilepsies

According to a story from sectorpublishingintelligence.co.uk, the drug company Ovid Therapeutics Inc. has recently announced that the early data from its phase 2 clinical trial is mostly encouraging. This clinical…

Continue Reading Initial Trial Data Looks Promising for a Potential Treatment for Rare Epilepsies

Two Phase 2 Clinical Studies of a Drug for Rare Epilepsies Have Been Initiated

Two Phase 2 clinical trials called ‘Elektra’ and ‘Arcade’ have been initiated. They will investigate the drug OV935/TAK-935 as a potential treatment for paediatric patients with rare epilepsies. For more…

Continue Reading Two Phase 2 Clinical Studies of a Drug for Rare Epilepsies Have Been Initiated
Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug
stevepb / Pixabay

Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug

  Takeda Pharmaceutical Company Limited and Ovid Therapeutics have released an overview of the clinical development program for TAK-935/OV935, an investigational drug that is being developed as a potential anti-epileptic…

Continue Reading Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug
Close Menu